ES2153444T3 - Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion. - Google Patents

Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion.

Info

Publication number
ES2153444T3
ES2153444T3 ES95108150T ES95108150T ES2153444T3 ES 2153444 T3 ES2153444 T3 ES 2153444T3 ES 95108150 T ES95108150 T ES 95108150T ES 95108150 T ES95108150 T ES 95108150T ES 2153444 T3 ES2153444 T3 ES 2153444T3
Authority
ES
Spain
Prior art keywords
antigens
production
mamifera
interleucine
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95108150T
Other languages
English (en)
Inventor
Frank Lee
Takashi Yokota
Ken-Ichi Arai
Timothy Mosmann
Donna Rennick
Craig Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/843,958 external-priority patent/US5552304A/en
Priority claimed from US06/908,215 external-priority patent/US5017691A/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2153444T3 publication Critical patent/ES2153444T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Fertilizers (AREA)
  • Auxiliary Devices For Music (AREA)

Abstract

SE PROPORCIONAN ANTICUERPOS PARA LA INTERLEUCINA-4 DE LOS MAMIFEROS Y MUTEINAS, ESPECIALMENTE PARA LA IL-4S NATIVA HUMANA, ASI COMO PEPTIDOS UTILES COMO ANTIGENOS EN SU PRODUCCION. SE DESCUBREN ACIDOS NUCLEICOS QUE SON CAPACES DE CODIFICAR PARA LA IL-4S DE LOS MAMIFEROS Y SUS MUTEINAS.
ES95108150T 1985-11-19 1986-11-19 Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion. Expired - Lifetime ES2153444T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US79966885A 1985-11-19 1985-11-19
US79966985A 1985-11-19 1985-11-19
US06/843,958 US5552304A (en) 1985-11-19 1986-03-25 CDNA Clones coding for human protein exhibiting a broad cellular activity spectrum (human interleukin-4)
US88155386A 1986-07-03 1986-07-03
US06/908,215 US5017691A (en) 1986-07-03 1986-09-17 Mammalian interleukin-4
EP86907184A EP0249613B1 (en) 1985-11-19 1986-11-19 Interleukin-4 protein having bcgf and tcgf activity on human cells (human interleukin-4)

Publications (1)

Publication Number Publication Date
ES2153444T3 true ES2153444T3 (es) 2001-03-01

Family

ID=27542219

Family Applications (2)

Application Number Title Priority Date Filing Date
ES86907184T Expired - Lifetime ES2088858T3 (es) 1985-11-19 1986-11-19 Proteina interleuquina-4 que tiene actividad de factor de crecimiento de celulas b(bcgf) y de factor de crecimiento de celulas t(tcgf) en celulas humanas (interleuquina-4 humana).
ES95108150T Expired - Lifetime ES2153444T3 (es) 1985-11-19 1986-11-19 Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES86907184T Expired - Lifetime ES2088858T3 (es) 1985-11-19 1986-11-19 Proteina interleuquina-4 que tiene actividad de factor de crecimiento de celulas b(bcgf) y de factor de crecimiento de celulas t(tcgf) en celulas humanas (interleuquina-4 humana).

Country Status (23)

Country Link
EP (3) EP0230107A1 (es)
JP (2) JP2557361B2 (es)
KR (1) KR940007773B1 (es)
CN (1) CN1020472C (es)
AT (2) ATE140009T1 (es)
AU (1) AU610057B2 (es)
CZ (1) CZ414191A3 (es)
DE (2) DE3650751T2 (es)
DK (1) DK371087A (es)
ES (2) ES2088858T3 (es)
FI (1) FI102075B (es)
GR (1) GR3021198T3 (es)
HK (2) HK1005594A1 (es)
HU (1) HU208710B (es)
IE (1) IE80828B1 (es)
IL (1) IL80678A (es)
MY (1) MY101972A (es)
NO (1) NO301234B1 (es)
NZ (1) NZ218332A (es)
OA (1) OA08947A (es)
PT (1) PT83761B (es)
SK (1) SK414191A3 (es)
WO (1) WO1987002990A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0740943B2 (ja) * 1985-09-30 1995-05-10 佑 本庶 新規なポリペプチドをコードするｄｎａ及びその製造方法
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5700915A (en) * 1985-11-19 1997-12-23 Schering Corporations Human interleukin immunopurification processes
US5912136A (en) * 1985-11-19 1999-06-15 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
AU620537B2 (en) * 1986-12-19 1992-02-20 Immunex Corporation Human interleukin-4 muteins
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
EP0301835A1 (en) * 1987-07-29 1989-02-01 Schering Biotech Corporation Purification of human interleukin-4 expressed in Escherichia Coli
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
ES2059453T3 (es) * 1987-08-03 1994-11-16 Tasuku Honjo Un procedimiento para la produccion de interleuquina 4 humana.
JPH03500050A (ja) * 1988-02-02 1991-01-10 シェリング・バイオテック・コーポレーション 免疫グロブリンｅの応答を減少させる方法
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB2218420B (en) * 1988-04-12 1992-07-15 British Bio Technology Synthetic gene encoding interleukin 4
EP0370090B1 (en) * 1988-05-13 1996-07-10 University Patents, Inc. Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens
US4958007A (en) * 1988-05-17 1990-09-18 Schering-Plough Corp. Extraction of human interleukin-4- from bacteria
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
EP0378827A1 (en) * 1988-12-21 1990-07-25 Schering Corporation Use of interleukin-4 for lowering blood glucose levels and/or effecting weight reduction
JPH0611706B2 (ja) * 1989-01-20 1994-02-16 ザ ユニバーシティ オブ メルボルン フィブリン溶解
US5077388A (en) * 1990-05-31 1991-12-31 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
US5449515A (en) * 1989-11-21 1995-09-12 University Of Melbourne Anti-inflammatory compositions and methods
SE465039B (sv) * 1989-11-23 1991-07-15 Chemrec Ab Saett att framstaella koklutar med hoeg sulfiditet foer sulfatmassakokning
US5188827A (en) * 1989-12-18 1993-02-23 Schering Corporation Use of interleukin-4- for lowering blood-cholesterol levels
CA2071908C (en) * 1989-12-20 2002-04-30 Lata Ramanathan Antibody antagonists of human interleukin-4
EP0521916B1 (en) * 1990-03-21 1996-01-17 Schering Corporation Use of il-4 to enhance immune response to infectious antigenic challenges
AU9161591A (en) * 1990-12-19 1992-07-22 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
EP0566661B1 (en) * 1991-01-10 1996-03-13 Schering Corporation Use of il-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
AUPN481295A0 (en) * 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
EP1083980B1 (en) * 1998-05-12 2007-03-21 Isis Pharmaceuticals, Inc. Modulation of molecular interaction sites on rna and other biomolecules
AUPQ005399A0 (en) * 1999-04-29 1999-05-27 Medvet Science Pty. Ltd. Agonists or antagonists for haemopoietic growth factors
EP3636274A1 (en) 2011-01-18 2020-04-15 Bioniz, LLC Compositions and methods for modulating gamma-c-cytokine activity
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
CN102212888A (zh) * 2011-03-17 2011-10-12 靳海峰 一种基于高通量测序的免疫组库构建方法
PL3359556T3 (pl) 2015-10-09 2021-11-22 Bioniz, Llc Modulowanie aktywności gamma-c-cytokin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US799668A (en) * 1905-05-29 1905-09-19 Albert R Pritchard Dough kneader and mixer.
US799669A (en) * 1905-07-27 1905-09-19 Eugene S Regnier Combined cutting and raking implement.
US843958A (en) * 1905-11-20 1907-02-12 Whitehead & Hoag Co Key-ring tag.
US4613459A (en) * 1982-10-20 1986-09-23 Dana-Farber Cancer Institute Lymphocyte growth factor
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
AU7082487A (en) * 1986-02-11 1987-08-25 University Of Texas System, The Recombinant human b-cell growth factor
ZA872781B (en) * 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
AU620537B2 (en) * 1986-12-19 1992-02-20 Immunex Corporation Human interleukin-4 muteins

Also Published As

Publication number Publication date
EP0249613B1 (en) 1996-07-03
EP0230107A1 (en) 1987-07-29
IL80678A (en) 1999-05-09
EP0675136A2 (en) 1995-10-04
MY101972A (en) 1992-02-29
DE3650751D1 (de) 2001-02-22
AU6733487A (en) 1987-06-02
ES2088858T3 (es) 1996-10-01
DE3650538D1 (de) 1996-08-08
AU610057B2 (en) 1991-05-16
NO872988L (no) 1987-09-18
HUT43630A (en) 1987-11-30
FI873141A0 (fi) 1987-07-16
DK371087A (da) 1987-09-21
PT83761A (en) 1986-12-01
ATE140009T1 (de) 1996-07-15
HK1005594A1 (en) 1999-01-15
NO872988D0 (no) 1987-07-17
EP0249613A1 (en) 1987-12-23
JP2557361B2 (ja) 1996-11-27
SK414191A3 (en) 1995-07-11
FI102075B1 (fi) 1998-10-15
OA08947A (en) 1990-11-30
ATE198754T1 (de) 2001-02-15
IE863042L (en) 1987-05-19
EP0675136A3 (en) 1996-03-13
GR3021198T3 (en) 1996-12-31
PT83761B (pt) 1989-06-30
NZ218332A (en) 1993-04-28
CZ414191A3 (en) 1993-04-14
CN1020472C (zh) 1993-05-05
HU208710B (en) 1993-12-28
DE3650751T2 (de) 2001-08-02
CN86108579A (zh) 1988-01-27
JP2568394B2 (ja) 1997-01-08
FI102075B (fi) 1998-10-15
JPS63501401A (ja) 1988-06-02
DK371087D0 (da) 1987-07-16
IL80678A0 (en) 1987-02-27
HK1008823A1 (en) 1999-05-21
FI873141A (fi) 1987-07-16
JPH0884591A (ja) 1996-04-02
DE3650538T2 (de) 1996-12-12
EP0675136B1 (en) 2001-01-17
NO301234B1 (no) 1997-09-29
KR940007773B1 (ko) 1994-08-25
WO1987002990A1 (en) 1987-05-21
IE80828B1 (en) 1999-03-10

Similar Documents

Publication Publication Date Title
ES2153444T3 (es) Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion.
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
ES2093640T3 (es) Produccion de hemoglobina y sus analogos mediante bacterias y levadura.
ES2056817T3 (es) Transformacion de trichoderma.
ES533485A0 (es) Procedimiento para producir un vehiculo de expresion de adn-replicable.
HUT44615A (en) Process for preparing gm-cst protein and its derivatives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 675136

Country of ref document: ES